検索ワード: apheresis (英語 - マルタ語)

apheresis catheter care sheets
skedi għall-kura tal-katiter tal-aferesi

the mobilisation and apheresis procedures should be performed in
il- kura b’ filgrastim għandha tingħata biss b’ kollaborazzjoni ma ’ ċentru ta ’ onkoloġija b’ esperjenza fil- kura bil- fattur uman li jistimola l- kolonji ta ’ granuloċiti (g- csf) u ematoloġija u fejn jinstabu l- meżżi dijanjostiċi kollha meħtieġa.

b n includes all patients who received at least one day of apheresis
b n jinkludi l-pazjenti kollha li rċivew mill-inqas jum wieħed ta’ aferesi

such apheresis donations take longer in time but can be organised more frequently.
donazzjonijiet ta' asferesi bħal dawn jieħdu aktar fit-tul iżda jistgħu jiġu organizzati aktar ta' spiss.

- are about to have a treatment called ldl apheresis for removal of cholesterol
- ser ikollok trattament imsejjaħ aferesi ta ’ ldl għat- tneħħija ta ’ kolesterol

platelet counts should be monitored in all patients receiving mozobil and undergoing apheresis.
l-għadd tal-plejtlits għandu jiġi mmonitorjat fil-pazjenti kollha li jkunu qed jirċievu mozobil u li tkun qed issirilhom l-aferesi.

thrombocytopenia is a known complication of apheresis and has been observed in patients receiving mozobil.
it-tromboċitopenja hi kumplikazzjoni magħrufa tal-aferesi u kienet osservata f’pazjenti li kienu qed jirċievu mozobil.

patients achieving ≥ 6 x 106 cells/kg in ≤ 2 apheresis days and successful engraftment
pazjenti li kisbu ≥ 6 x 106 ċelluli/kg f’≤ jumejn ta’ aferesi u engraftment li rnexxa

adverse reactions occurring more frequently with mozobil than placebo and considered related to mozobil during mobilisation and apheresis in phase iii studies
reazzjonijiet avversi li seħħew b’mod aktar frekwenti b’mozobil milli bil-plaċebo u li huma kkunsidrati li huma marbuta ma’ mozobil matul il-mobilizzazzjoni u l- aferesi fi studji ta’ fażi iii

the clinical benefit of reductions in background lipid-lowering therapy, including apheresis, is not certain.
il- benefiċċju kliniku tat-tnaqqis fit-terapija ta’ sfond li tnaqqas il-lipidi, inkluż aferesi, mhuwiex ċert.

for the purpose of haematopoietic stem cell mobilisation, plerixafor may cause mobilisation of leukaemic cells and subsequent contamination of the apheresis product.
għall-iskop tal-mobilizzazzjoni taċ-ċelluli staminali ematopojetiċi, plerixafor jista’ jikkawża l-mobilizzazzjoni ta’ ċelluli lewkemiċi u kontaminazzjoni sussegwenti tal-prodott tal-aferesi.

the mah shall also agree with the national competent authority any requirements for prior audit of apheresis centres and training courses for healthcare professionals in the use of provenge.
l-mah għandu jaqbel ukoll mal-awtorità nazzjonali kompetenti dwar kwalunkwe rekwiżit għall-verifika minn qabel ta’ ċentri ta’ aferesi u korsijiet ta’ taħriġ għall-professjonisti fil- kura tas-saħħa fl-użu ta’ provenge.

in sum, the undertaken study indicates that there are no major differences in incentives for whole blood and apheresis donors in the eu, norway and croatia.
Ġeneralment, l-istudju li sar jindika li ma hemm l-ebda differenzi kbar fl-inċentivi għad-donaturi tad-demm sħiħ u d-donaturi tal-aferesi fl-ue, fin-norveġja u fil-kroazja.

it is recommended that the apheresis centre perform a systematic record and tracking of the stem cell donors for at least 10 years to ensure monitoring of long-term safety.
huwa rakkomandat li jinżammu rekords sistematiċi tad-donaturi taċ-ċelluli proġentriċi mill-inqas għal għaxar snin fiċ-centru fejn issir l-afereż ta’ pbpc sabiex ikun assigurat l- monitoraġġ u s-sigurta’ fit-tul.

during donations of blood components, the needed components are separated from the blood and the remainder is thereafter returned to the donors in a so-called apheresis process.
matul id-donazzjonijiet ta' komponenti tad-demm, il-komponenti meħtieġa jiġu sseparati mid-demm u l-bqija jintbagħtu lura lid-donaturi bl-hekk imsejjaħ proċess aferesi.

the mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
il-proċeduri tal-mobilizzazzjoni u l-aferesi għandhom jitwettqu b’kollaborazzjoni ma’ ċentru tal-onkoloġija-ematolġija b’esperjenza aċċettabbli f’dan il- qasam u fejn il-monitoraġġ taċ-ċelluli ematopojetiċi proġenituri jkun jista’ jitwettaq b’mod korrett.

during that 24-hour period, the first dose of plerixafor 0.24 mg/kg or placebo was administered 10-11 hours prior to apheresis.
matul dak il-perijodu ta’ 24 siegħa, l-ewwel doża ta’ plerixafor 0.24 mg/kg jew plaċebo ngħatat 10-11-il siegħa qabel l-aferesi.

study amd3100-3102 – proportion of patients who achieved ≥ 6 x 106 cd34+ cells/kg by apheresis day in multiple myeloma patients
studju amd3100-3102 – il-proporzjon ta’ pazjenti li kisbu ≥ 6 x 106 cd34+ ċelluli/kg sal-jum tal-aferesi f’pazjenti li kellhom majeloma multipla

in pivotal clinical studies supporting the use of mozobil, all patients received daily morning doses of 10 g/kg g-csf for 4 consecutive days prior to the first dose of plerixafor and on each morning prior to apheresis.
fi studji kliniċi importanti ħafna li jappoġġjaw l-użu ta’ mozobil, il-pazjenti kollha rċivew ta’ kuljum filgħodu dożi ta’ 10 g/kg g-csf għal 4 ijiem konsekuttivi qabel l-ewwel doża ta’ plerixafor u kull filgħodu qabel l-aferesi.

if more than one leukapheresis is required, particular attention should be paid to donors with platelets < 100 x 109/l prior to leukapheresis; in general apheresis should not be performed if platelets < 75 x 109/l.
jekk iktar minn lewkaferesi waħda tkun meħtieġa, għandha tingħata attenzjoni partikulari għal donaturi b’għadd tal-plejtlits ta’ < 100 x 109/l qabel il-lewkaferesi; b’mod ġenerali l-aferesi m’għandhiex titwettaq jekk l-għadd tal-plejtlits ikun ta’ < 75 x 109/l.